A Prospective Trial to Identify Biomarkers Involved in the Transition From Acute to Persistent Chronic Low Back Pain
A Prospective Controlled Trial to Identify Biomarkers Involved in the Transition From Acute to Persistent Chronic Low Back Pain
1 other identifier
observational
5,000
6 countries
7
Brief Summary
This is a prospective observational cohort multinational clinical study. There are no biomarkers to help predict in which patients acute low back pain (LBP) will transform into chronic low back pain (CLBP). Human variability and different common comorbidities complicate the picture and make stratification of patients into correct subgroups difficult. However, drugs act by targeting specific molecular pathways and are therefore efficient only in a subgroup of patients sharing common molecular pathology and common genetics. Both CLBP and disc degeneration are known to be heritable. Little investigation has taken place for genetic variants in CLBP. The main aim of this trial is to identify "omics biomarkers" associated with the transition from acute (single episode of low back pain) to persistent/chronic LBP (pain lasting more than 12 weeks).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2014
Typical duration for all trials
7 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 14, 2014
CompletedFirst Posted
Study publicly available on registry
January 16, 2014
CompletedStudy Start
First participant enrolled
December 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2018
CompletedSeptember 26, 2016
September 1, 2016
3.7 years
January 14, 2014
September 22, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Genetic outcome
To investigate the associations between genetic factors and the development of persistent chronic LBP, in patients developing persistent chronic symptoms (defined as pain that persists 3 months or more), after an episode of acute LBP. The development of persistent chronic pain will be assessed at 3 months after the acute episode. Existing and newly generated GWAs will be analyzed and their possible correlation with the risk of pain becoming persistent chronic will be detected in a wide, international population of caucasian ancestry.
54 months
Secondary Outcomes (6)
Glycomic and Activomic outcome
54 months
Epigenetic outcome
54 months
Next-generation sequencing outcome
54 months
Stratification based on pain characteristics
54 months
Stratification based on pain pathophysiology
54 months
- +1 more secondary outcomes
Eligibility Criteria
Each clinical centre will identify patients with an episode of acute LBP, with or without irradiation, referred from primary care physicians, orthopaedic specialists or directly selected in the emergency room (accessing hospital for acute low back pain). The enrolment will be competitive among the participating clinical centres.
You may qualify if:
- age: older than 18;
- acute episode of pain between the costal margins and gluteal fold, with or without symptoms into one or both legs lasting less than 6 weeks;
- written informed consent signed;
- Caucasian ancestry
You may not qualify if:
- evidence of clinically unstable disease;
- severe psychiatric disorder (excluding mild depression) or mental impairment;
- history (in the last 6 months) of persistent chronic low back pain or acute LBP episodes
- recent history (\< 1 year) of spinal fracture;
- pain in the back due to spinal tumor or infection;
- pregnancy;
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Parmalead
- GENOScollaborator
- Ip Research Consulting Sasucollaborator
- Helmholtz Zentrum Münchencollaborator
- YURII AULCHENKOcollaborator
- King's College Londoncollaborator
Study Sites (7)
The Center for Clinical Research (CPI)
Winston-Salem, North Carolina, United States
Edith Cowan University (ECU)
Perth, Australia
Multidisciplinary Pain Centre, Hospital Oost-Limburg (ZOL)
Genk, Belgium
"St.Catharine" Orthopedics, Surgery, Neurology and Physical Medicine and Rehabilitation Specialty Hospital (St-Cat)
Zabok, Croatia
Anesthesia and Pain Therapy Department, Università degli Studi di Parma (UNIPR)
Parma, Italy
Fondazione IRCCS Policlinico San Matteo (OSM)
Pavia, 27100, Italy
King's College London (KCL)
London, United Kingdom
Biospecimen
Whole blood samples will be collected at recruitment in all enrolled patients. Blood samples will be collected also at the 3 months and 6 months follow up visits in patients who will develop CLBP after the episode of acute LBP.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
MASSIMO ALLEGRI, MD
Pain Therapy Service Azienda Ospedaliera Universitaria Parma Italy
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD
Study Record Dates
First Submitted
January 14, 2014
First Posted
January 16, 2014
Study Start
December 1, 2014
Primary Completion
August 1, 2018
Study Completion
August 1, 2018
Last Updated
September 26, 2016
Record last verified: 2016-09